Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Assessment of the Nutritional Status of Patients Undergoing Prosthetic Orthopedic Surgery: An Exploratory Study

NCT07782502 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-09-01
Last updated
2026-08-24

Condition(s) studied

Total Knee Anthroplasty

Investigational drug(s) / intervention(s)

Blood and physical performance tests

Blood and physical performance tests: Additional postoperative blood tests. Physical performance test (hand grip-test, measurement of the calf circumference of the non-operated leg, walking test, chair stand test and Timed Up \& Go test.

Study summary

The aim of this study is to evaluate the impact of prosthetic orthopedic surgery on the nutritional status of patients undergoing total knee arthroplasty in adult patients scheduled.

This study is based on the hypothesis that prosthetic orthopedic surgery may induce or worsen malnutrition, an issue that has not been investigated to date.

Participants will perform an additionnal blood test, physical performance tests and questionnaires as part of this research.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Male or female patients aged ≥18 years at the time of surgery * Patients scheduled for total knee arthroplasty. * Patients enrolled in the preoperative Enhanced Recovery After Surgery (ERAS) pathway. * Patients affiliated with or covered by a social security system. * French-speaking patients who have provided written informed consent Exclusion Criteria: * Patients scheduled for revision total knee arthroplasty * Protected patients: adults under guardianship, curatorship, or other legal protection measures, or individuals deprived of liberty by judicial or administrative decision * Patients hospitalized without consent.

Primary outcome measure(s)

  • Patients nutritional status — At baseline and 1 month follow-up.
    The primary outcome measure is the prevalence of patients with a low Prognostic Nutritional Index (PNI) (PNI \< 40). PNI value ≥ 50: Normal; PNI value \< 50: Mild malnutrition; PNI value\< 45: Moderate to severe malnutrition; PNI value\< 40: Serious malnutrition.

Trial sites (1)

FacilityCityRegionStatus
Clinique des Maussins Paris France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07782502 on ClinicalTrials.gov ↗ ← All trials in France